- Windward Bio gets $165M to take China-derived drug into Phase 3 asthma trialA Swiss biotech with two experimental medicines from China, plus an in-house discovery team, has brought in $165 million to advance into late-stage testing. The startup, Windward Bio, has raised…Endpoints · 2mo ago↗ source
- UCB bets $2B on Candid's T cell engager ambitionsKen Song has done it again. The biopharma veteran's all-out effort to prove T cell engagers' potential in autoimmune diseases is getting picked up by one of Europe’s oldest pharma companies. UC…Endpoints · 2mo ago↗ source
- Bristol Myers’ pivotal year; Should AI be swinging bigger?; and moreWelcome back to Endpoints Weekly! The last week of April brought a downpour of news as several pharma companies reported their first-quarter earnings. Max Gelman took a close look at a make-or-brea…